Abstract
Objective: To explore whether human umbilical cord blood hematopoietic progenitor cells transduced with human O6-methylguanine-DNA-methyltransferase (MGMT) gene could increase resistance to 1,3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU). Methods: The cDNA encoding the MGMT was isolated by using RT-PCR method from total RNA of fresh human liver, the fragment was cloned into pGEM-T vector and further subcloned into G1Na retrovirus vector. Then the GlNa-MGMT was transduced into the packaging cell lines GP+E86 and PA317 by LipofectAMINE. By using the medium containing BCNU for cloning selection and ping-ponging supernatant infection between ecotropic producer clone and amphotropic producer clone, high titer amphotropic PA317 producer clone with the highest titer up to 5.8xlO5 CFU/ml was obtained. Cord blood CD34+ cells were transfected repeatedly with supernatant of retrovirus containing human MGMT-cDNA under stimulation of hemopoietic growth factors. Results: The retrovirus vector construction was verified by restriction endonuclease analysis and DNA sequencing. PCR, RT-PCR, Southern Blot, Western Blot and MTT analyses showed that MGMT drug resistance gene has been integrated into the genomic DNA of cord blood CD34+ cells and expressed efficiently. The transgene cord blood CD34+ cells conferred 4-folds stronger resistance to BCNU than untransduced cells. Conclusion: The retrovirus vector-mediated transfer of MGMT drug resistance gene into human cord blood CD34+ cells and its expression provided an experimental foundation for gene therapy in clinical trial.
Similar content being viewed by others
References
Reese JS, Koc ON, Lee KM, et al. Retroviral transduction of a mutant methylguanine-DNA-methyltransterase gene into CD34+ cells Confers resistance to O6-benzylguanine plus 1,3-bis (2-chloroethyl)-l-nitrosourea. Proc Natl Acad Sci USA 1996; 93: 14088.
Maze R, Carney JP, Kelly MR, et al. Increasing DNA repair methyl-transferase levels via bone marrow cell transduction rescues mice from the toxic effects of 1,3-bis (2-chloroethyl)-l-nitrosourea. Chemotherapeutic alkylating agent. Proc Natl Acad Sci SUA 1996; 93: 206.
Smith MA, McCaffrey RP, Karp JE, et al. The secondary leukemias: challenges and research directions. J Natl Catl Cancer Inst 1996; 88: 407.
Harris LC, Marathi UK, Edwards CC, et al. Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethyl-nitrosourea cytotoxicity. Clin Cancer Res 1995; 1: 1359.
Lynch CM, Miller AD. Production of high-titer helper virus-free retroviral vectors by cocultivation of packaging cells with different host ranges. J Virol 1991; 65: 3887.
Allay JA, Dumemco LL, Koc ON, et al. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistsance to hematopoietic cells. Blood 1995; 85: 3342.
Moritz T, Mackay W, Glasner BL, et al. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicityin vivo. Cancer Res 1995; 55: 2608.
Deisseroth AB, Holmea F, Hortobagyi RC, et al. Hamplin. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoieticells for chemoprotectior, during the therapy of breast cancer: a pilot trial. Hum Gene Ther 1996; 7: 401.
Hildinger M, Fehse B, Hegewisch-becker S, et al. Dominant selection of hematopoietic progenitor cells with retroviral MDR1 co-exopression vectors. Hum Gen ther 1998; 9: 33.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, Js., Chen, Zx., Xia, Xm. et al. In vitro study on the cloning and transduction of human O6-methylguanine-DNA-methyltransferase cDNA into human umbilical cord blood CD34+ cells. Chin J Cancer Res 12, 115–119 (2000). https://doi.org/10.1007/BF02983435
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02983435